GH1 and pancreatic insulinoma: SSAs can paradoxically worsen hypoglycaemia in insulinoma patients due to their preferential suppression of hormones that induce hyperglycaemia (i.e. glucagon and growth hormone), which resolves post cessation of SSA therapy (Stehouwer et al. 1989, Abell et al. 2015).